Illumina, Inc.
Stocks
TJX Companies, Inc. (The)
Stocks
Illumina, Inc. vs TJX Companies, Inc.: A Data-Driven Comparison for Investment Experts
Last updated: June 2, 2026
Summary
Illumina, Inc. and TJX Companies, Inc. operate in vastly different sectors, offering distinct investment profiles. While Illumina leads in healthcare diagnostics with a higher valuation based on its growth metrics, TJX excels with a larger market cap and dividend yield, appealing to value-focused investors. This comparison provides data-backed insights for expert-level investors evaluating these stocks.
Key Differences at a Glance
| Aspect | Illumina, Inc. | TJX Companies, Inc. (The) | Winner |
|---|---|---|---|
| Market Capitalization | $24.87 billion | $168.91 billion | TJX Companies, Inc. (The) |
| Revenue | $4.39 billion | $61.58 billion | TJX Companies, Inc. (The) |
| Profit Margin | 19.42% | 9.40% | Illumina, Inc. |
| Beta (volatility measure) | 1.424 | 0.637 | TJX Companies, Inc. (The) |
| Dividend Yield | N/A | 1.24% | TJX Companies, Inc. (The) |
Market Capitalization: TJX Companies' market cap of approximately $169 billion significantly surpasses Illumina’s $24.87 billion, reflecting its larger scale and broad retail footprint, which offers more stability and liquidity for institutional investors.
Revenue: TJX’s revenue of nearly $61.6 billion vastly exceeds Illumina’s $4.39 billion, highlighting its dominant position in the global apparel retail market and its capacity for high sales volume.
Profit Margin: Illumina’s profit margin of 19.42% exceeds TJX’s 9.40%, indicating higher operational efficiency and profitability in its diagnostics and research niche, which is essential for growth-focused investors.
Beta (volatility measure): TJX’s lower beta of 0.637 suggests it is less volatile and more defensive, making it more suitable for risk-averse investors compared to Illumina’s higher beta of 1.424.
Dividend Yield: TJX offers a dividend yield of 1.24%, providing income for investors, whereas Illumina does not currently pay dividends, aligning with its growth-oriented profile.
Detailed Analysis
Illumina, Inc. is a healthcare technology company specializing in genomic sequencing, with a market capitalization of approximately $24.87 billion and revenue of $4.39 billion. Its focus on diagnostics and research positions it as a key player in personalized medicine and biotech innovation. The company's EPS of $5.51 and a PE ratio of roughly 29.84 reflect strong profitability and investor confidence in its growth prospects. Its beta of 1.424 indicates higher volatility, typical for biotech stocks, which are often influenced by regulatory developments and technological breakthroughs.
In contrast, TJX Companies, Inc., with a market cap of around $169 billion, dominates the apparel retail sector through its extensive portfolio of discount stores. Its revenue of $61.58 billion underscores its operational scale, and its profit margin of 9.40% demonstrates efficient cost management within a highly competitive sector. TJX’s lower beta of 0.637 signals less price volatility, making it more attractive to conservative investors. Furthermore, its dividend yield of 1.24% offers a steady income stream, which is rare in retail stocks with such high revenue figures.
From an investment perspective, Illumina’s higher profit margin and growth potential in biotech give it an edge for growth-oriented investors valuing innovation and higher risk-reward ratios. Conversely, TJX’s larger market cap, dividend yield, and lower volatility make it appealing for value investors seeking stability and income. The PE ratios are nearly identical at approximately 29.8, indicating that both stocks are currently valued fairly relative to earnings, but their sector dynamics and risk profiles differ substantially.
Expert investors should consider these metrics in conjunction with sector trends—healthcare tech versus consumer retail—when making allocations. Illumina’s higher beta suggests it is more sensitive to biotech sector shifts, while TJX’s stability stems from its established retail operations and diversified geographic presence. Ultimately, the choice depends on risk appetite: Illumina for growth and innovation, TJX for stability and income generation.
Verdict
Illumina, Inc. is the preferred choice for investors seeking high-growth potential and technological innovation in the healthcare sector, despite its higher volatility. TJX Companies, Inc., on the other hand, offers a more stable investment with substantial market presence, dividend income, and lower risk, making it ideal for conservative investors prioritizing income and stability in the retail industry.
Who Should Choose What
Choose Illumina, Inc. if...
Best for growth-focused investors interested in biotech innovation, high profit margins, and potential for future breakthroughs in genomics and diagnostics.
Choose TJX Companies, Inc. (The) if...
Best for value and income investors looking for stability, dividend income, and lower volatility within a large-scale retail enterprise.